01 Dec 21 | CN | Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the treatment of patients with advanced, metastatic or recurrent...
Pearce IP BioBlast® w/e 03 December 2021
read more
Pearce IP is Intellectual Property Team of the Year
Australian Law Awards (Lawyers Weekly)
It is our great privilege to share that Pearce IP was honoured as “Intellectual Property Team of the Year” at the Lawyers Weekly Australian Law Awards (2021) on 2nd December. ...
Pearce IP BioBlast® w/e 26 November 2021
21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated...
Breaking News – Parliament delivers early Christmas present for Health Care
In the last sitting of Parliament for 2021, the House of Representatives delivered the long-awaited Zimmerman Report, more formally entitled “The new frontier—delivering better...
Naomi Pearce is Lawyers Weekly WIL Partner of the Year 2021
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, was awarded the title of 2021 Partner of the Year...
Disclaimer amendment allowed in mastitis patent
Boehringer Ingelheim Animal Health USA Inc v Elanco New Zealand [2021] FCA 1457
Date: 25 November 2021Court: Federal Court of AustraliaJudge: Besanko J Background This appeal from a decision of the Australian Patent Office concerned the allowability of...
Pearce IP BioBlast®: w/e 19 November 2021
15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with COVID-19 who do not require supplemental oxygen and who are at...
No jackpot for Aristocrat as Full Court finds electronic gaming machine claim unpatentable
Commissioner of Patents v Artistocrat Technologies Australia Pty Ltd (2021) FCAFC 202
Date: 19 November 2021Court: Full Court of the Federal Court of AustraliaJudges: Middleton, Perram and Nicholas JJ Background In 2018 the Australian Patent Office refused to...
Pfizer quest for Samsung Bioepsis etanercept documents continues
Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 3) [2021] FCA 1428
Date: 18 November 2021Court: Federal Court of AustraliaJudge: Burley J Background In December 2016 Pfizer Ireland Pharmaceuticals (Pfizer) filed a preliminary discovery...
Hold onto your Hats! – Expedited Patent Litigation in Australia
The speed of getting a case to trial is a key metric of any litigation system. Pharmaceutical patent litigation often plays out on the cusp of patent expiry when a new market...
Pearce IP BioBlast®: w/e 12 November 2021
09 Nov 21 | Coherus BioSciences reported its Q3 2021 financial results. Coherus announced that FDA review of CHS-201 (proposed adalimumab biosimilar) is advancing towards the...
Pearce IP BioBlast®: w/e 05 November 2021
01 Nov 21 | The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to join the Biosimilars Movement...
PTE Alert: Recent cases create fertile ground for PTE challenges
In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the Australian Patent Office’s interpretation of the eligibility...
Pearce IP BioBlast®: w/e 29 October 2021
22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on year. 22 Oct 21 | Chugai Pharmaceutical announced that it will...
Pearce IP BioBlast®: w/e 22 October 2021
14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin glargine biosimilar. 15 Oct 21 | US | Roche announced that the...
Strategies for generic/biosimilar market entry in Australia
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second...
Is best practice for patent validity in Australia an impossible task?
The evolution of jurisprudence in Australia can have far reaching implications for legal practitioners in every jurisdiction. Two recent Federal Court decisions have given...
Pearce IP BioBlast®: w/e 15 October 2021
05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of COVID-19 in...
Which product infringes? Kangatech ordered to file evidence consistent with pleadings despite later workaround
Vald Performance Pty Ltd v Kangatech Pty Ltd [2021] FCA 539; Vald Performance Pty Ltd v Kangatech Pty Ltd (No 3) [2021] FCA 1265
Date: 20 May 2021 / 18 October 2021Court: Federal Court of AustraliaJudge: Greenwood J Background Australian Patent 2012388708 (Patent) relates to a device and its use in sports...
Naomi Pearce Shortlisted for Lawyer’s Weekly Partner of the Year (SME Law), Women In Law Awards 2021
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, has been shortlisted as a finalist in the Lawyers...
Pearce IP BioBlast®: w/e 08 October 2021
27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal,...
Pearce IP honours UN International Day of the Girl Child by helping to end slavery
October 11 is UN International Day of the Girl Child, a day where we together recognise the unique challenges girls face around the world and seek to advance the rights of girls...
MSD and Pfizer pneumococcal conjugate vaccine settlement prolongs uncertainty regarding Australian product claims
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement and licence agreement with Pfizer Inc. in relation to MSD’s...
Pearce IP BioBlast®: w/e 01 October 2021
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.